MCC
RNAM

Money Concepts Capital’s Avidity Biosciences RNAM Stock Holding History

Money Concepts Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-71
Closed -$1.57K – 2390
2022
Q4 		$1.57K Buy
+71
New +$1.06K ﹤0.01% 2767

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Money Concepts Capital's RNAM Position: Q1 2023 in Review

Money Concepts Capital sold out of Avidity Biosciences (RNAM) in Q1 2023, closing a stake of 71 shares — an estimated $1.57K sold.

Money Concepts Capital first reported a position in RNAM in Q4 2022 and held it in 1 quarter. The position peaked at $1.57K in Q4 2022. 139 funds tracked by Wall St. Rank hold RNAM as of Q1 2023.

  • Money Concepts Capital reported no remaining Avidity Biosciences position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 71 Avidity Biosciences shares in Q1 2023, an estimated $1.57K.
  • Money Concepts Capital first reported a position in Avidity Biosciences in Q4 2022 and held it in 1 quarter.
  • Money Concepts Capital's Avidity Biosciences position peaked at $1.57K in Q4 2022.
  • 139 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.